STAAR Surgical | STAA

Stock Price
56.45
Daily Change
-2.17%
Yearly
-17.71%
Q2 Forecast
56.03
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Abbott 103.76 -0.44 -0.42% -10.87%
Atrion 542.42 -8.00 -1.45% -12.09%
Boston Scientific 51.40 -0.42 -0.81% 30.52%
Cerus 2.26 0 0% -54.98%
Cooper Companies 353.55 -2.92 -0.82% 2.59%
Exact Sciences 84.95 1.11 1.32% 81.94%
Hologic 79.04 -0.02 -0.03% 5.20%
J&J 158.39 1.42 0.90% -10.21%
Merit Medical Systems 83.95 -0.40 -0.47% 36.50%
Novartis 90.38 1.01 1.13% 5.18%
Orthofix International 19.68 -0.21 -1.06% -28.23%
OraSure Technologies 5.48 -0.24 -4.20% 62.61%
Rockwell Medical 4.56 0.34 8.06% 204.00%
Sientra 1.59 -0.04 -2.45% 55.88%
STAAR Surgical 56.45 -1.25 -2.17% -17.71%
Utah Medical Products 93.26 -1.74 -1.83% 10.34%
Bausch Health Companies 10.67 -0.39 -3.53% -7.70%

Indexes Price Day Year
USND 13229 -11.34 -0.09% 9.68%
US2000 1807 -24.19 -1.32% -4.40%

STAAR Surgical

STAAR Surgical traded at $56.77 this Monday June 5th, decreasing $0.93 or 1.61 percent since the previous trading session. Looking back, over the last four weeks, STAAR Surgical lost 16.06 percent. Over the last 12 months, its price fell by 17.24 percent. Looking ahead, we forecast STAAR Surgical to be priced at 56.03 by the end of this quarter and at 51.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

STAAR Surgical Company is a developer, producer, and marketer of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company's principal products are implantable Collamer lenses (ICLs) and intraocular lenses (IOLs). ICLs, consists of the Company’s ICL family of products, including the Toric implantable Collamer lenses (TICL) and EVO+ Visian ICL, are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness), hyperopia (far-sightedness), astigmatism, and presbyopia. IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts, and include the Company’s lines of silicone IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). The Company sells its products in more than 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore.